There are no adequate or well controlled studies of bevacizumab in pregnant women. While it is 590 not known if bevacizumab crosses the placenta, human IgG is known to cross the placenta. 591 Reproduction studies in rabbits treated with approximately 1 to 12 times the recommended human 592 dose of bevacizumab demonstrated teratogenicity, including an increased incidence of specific gross 593 and skeletal fetal alterations. Adverse fetal outcomes were observed at all doses tested. Other 594 observed effects included decreases in maternal and fetal body weights and an increased number of 595 fetal resorptions. [See Nonclinical Toxicology (13.3).] 596 Because of the observed teratogenic effects of bevacizumab in animals and of other inhibitors of 597 angiogenesis in humans, bevacizumab should be used during pregnancy only if the potential benefit 598 to the pregnant woman justifies the potential risk to the fetus.